Zymeworks Inc. is a privately held computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. Zymeworks is entering into strategic collaborations to optimize existing therapeutics, and is committed to building a pipeline of antibody-based therapeutics through improving failed or abandoned assets. Furthermore, Zymeworks is exploring the improvement of marketed protein therapeutics and to create second generation versions with improved efficacies. Our cross functional teams use Zymeworks’ integrated modeling, simulation and analysis platforms ZymeCAD™ and ResidueNetworks™ in combination with biochemical and biophysical data to design and optimize therapeutic antibodies.
Optimizing Therapeutic Antibodies
Zymeworks’ proprietary computational platform, ZymeCAD™, provides unparalleled insight into the structure-function relationships of proteins. Our scientists use the insight gained from detailed molecular simulations, along with our novel ResidueNetworks™ analysis capability, to optimize new and existing therapeutics by tailoring specific characteristics into antibodies via targeted changes to the amino acid sequences.
| Zymeworks Closes $3.5 Million Round of Financing and Announces Changes to its Board of Directors | 06/23/2009 - 07:00 | $3Million |
| Zymeworks Inc. announces closing of $1.3 million financing and addition to the board of directors | 03/03/2008 - 08:00 | $1Million |
| Zymeworks Receives $235,000 NRC-IRAP Funding | 05/09/2005 - 07:00 | $0Million |